Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Immunotherapy, Adoptive × CNS × Clear all

Phase

Status

Unknown 2 Terminated 2 Recruiting 2 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 CNS 1

Conditions

Interventions

Temozolomide 16 Magnetic Resonance Spectroscopy 15 Radiosurgery 10 Radiotherapy 9 Bevacizumab 9 Specimen Handling 6 Methotrexate 6 pembrolizumab 5 Surgical Procedures, Operative 5 Radiation 5 Topotecan 4 TIC10 compound 4 Isotretinoin 4 Carboplatin 4 abemaciclib 3 Trastuzumab 3 Thiotepa 3 Standard of Care 3 Nivolumab 3 Magnetic Resonance Imaging 3 Lomustine 3 Drug Therapy 3 Dexamethasone 3 thymoglobulin 2 pazopanib 2 lutetium Lu 177 dotatate 2 keyhole-limpet hemocyanin 2 imetelstat 2 fludarabine phosphate 2 fluciclovine F-18 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02575261 2020-07-16

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡